NASDAQ:XRTX XORTX Therapeutics Q3 2025 Earnings Results & Report $0.84 -0.05 (-5.73%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$0.84 0.00 (0.00%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. XORTX Therapeutics reported Q3 2025 earnings on November 14, 2025. The company reported EPS of -$0.65. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeAfter Market ClosesConference Call DateNovember 13, 2025Conference Call6:00 PM ET XORTX Therapeutics EPS ResultsActual EPS-$0.65Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AXORTX Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile XORTX Therapeutics Q3 2025 Earnings FAQ Did XORTX Therapeutics beat earnings estimates for Q3 2025? XORTX Therapeutics (NASDAQ:XRTX) reported earnings of -$0.65 per share for Q3 2025. The report was announced on Friday, November 14, 2025. XORTX Therapeutics Earnings HeadlinesXORTX Hikes on Revealing Drug SupplyNovember 16, 2026 | baystreet.caXORTX Completes Manufacturing of Clinical Drug SupplyNovember 16, 2026 | globenewswire.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 22 at 1:00 AM | Profits Run (Ad)XORTX Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 14, 2026 | marketscreener.comMXORTX Patent Allowed for XRx-101 Program by Japan Patent OfficeNovember 13, 2026 | globenewswire.comXORTX Therapeutics Inc XRTXOctober 16, 2026 | morningstar.comMSee More XORTX Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XORTX Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XORTX Therapeutics and other key companies, straight to your email. Email Address About XORTX TherapeuticsXORTX Therapeutics (NASDAQ:XRTX) is a clinical-stage biotechnology company headquartered in Calgary, Alberta. It develops treatments for progressive kidney diseases, with a focus on conditions that can lead to declining kidney function. The company’s research programs include XRx-008 for autosomal dominant polycystic kidney disease, XRx-101 for acute kidney injury, and XRx-225 for diabetic nephropathy. These programs are investigational and are not marketed therapies. XORTX’s approach focuses on purine metabolism and the enzyme xanthine oxidase, which the company is studying as a target for reducing processes associated with kidney injury and disease progression.View XORTX Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.